Sanofi has entered into an alliance with Provention Bio for the US commercialization of teplizumab, a potential gamechanger in the field of type 1 diabetes which has shown in studies it can delay onset of the disease by three years.
The deal is an interesting development for Sanofi, which in recent years has de-prioritized its former blockbuster insulin brands. It...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
